Therefore, this review aims to depict the complexity of the immune system in the glioma microenvironment, including the role of the PD-1/PD-L1 axis and adenosine pathway in the maintenance of immunosuppression and resistance to glioma treatments. This evidence concerns the gene CD274 and central nervous system cancer.